HBM (HKG:2142) subsidiary Nona Biosciences and Candid Therapeutics signed a research collaboration and license agreement for next-generation T-cell engagers, according to a Monday filing with the Hong Kong Exchange.
As part of the deal, Nona will be able to receive $320 million in upfront and potential milestone payments, the report said.
Candid will take charge of the subsequent development of the T-cell engagers, which kill cancer cells, the filing said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。